GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024. In the quarter to June 2026, revenue grew 25.7%, EPS grew 19.5% and free cash flow fell 4.95%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow GRAL
GRAIL, Inc. (GRAL) EV/Sales
As of 16 October 2026, GRAIL, Inc. (GRAL) trades at a EV/Sales of 25.5×. Over the past ten years it has ranged from −5.5× (September 2024) to 35.0× (October 2026); the current reading is higher than 97% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 15.2× | — |
| FY2024 | −1.5× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 12.6× | 53.97% |
| Mar 2026 | 8.2× | (46.28%) |
| Dec 2025 | 15.2× | 35.34% |
| Sep 2025 | 11.3× | 22.08% |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RDNT RadNet, Inc. compare | 2.6× |
| QGEN QIAGEN N.V. compare | 4.9× |
| VCYT Veracyte, Inc. compare | 5.3× |
| SHC Sotera Health Company compare | 5.7× |
| CDNA CareDx, Inc. compare | 6.4× |
| BLLN BillionToOne, Inc. compare | 10.3× |
| ADPT Adaptive Biotechnologies Corporation compare | 12.4× |
| TWST Twist Bioscience Corporation compare | 18.8× |
| GRAL GRAIL, Inc. | 25.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)